Legis Daily

VA Medicinal Cannabis Research Act of 2023

USA118th CongressHR-1003| House 
| Updated: 3/13/2023
J. Luis Correa

J. Luis Correa

Democratic Representative

California

Cosponsors (11)
Christopher R. Deluzio (Democratic)Maxwell Frost (Democratic)Daniel T. Kildee (Democratic)Jasmine Crockett (Democratic)Nancy Mace (Republican)Val T. Hoyle (Democratic)Earl Blumenauer (Democratic)Seth Moulton (Democratic)Zoe Lofgren (Democratic)Jason Crow (Democratic)Jack Bergman (Republican)

Health Subcommittee, Veterans' Affairs Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
VA Medicinal Cannabis Research Act of 2023 This bill requires the Department of Veterans Affairs (VA) to study the effects of cannabis on veterans who are enrolled in the VA health care system and have been diagnosed with post-traumatic stress disorder (PTSD) or chronic pain (i.e., eligible veterans). First, the bill requires the VA to conduct an observational, 18-month study on the effects of cannabis on the health outcomes of eligible veterans. The VA must report on the study and address whether it is able to meet criteria necessary to conduct clinical trials. Then, if the VA determines that it is able to proceed, it must carry out a series of clinical trials on the effects of cannabis appropriate for investigational use, as determined by the Food and Drug Administration, on the outcomes of eligible veterans. The VA must carry out a long-term observational study of the clinical trial participants. The VA may terminate the trials if it is unable to meet clinical guideline requirements or the trials would create excessive risk to participants. The VA must ensure that the study and trials are representative of the demographics of veterans in the United States, as determined by the most recent data from the American Community Survey of the Bureau of the Census. The study and trials must include mechanisms to ensure data preservation and registration as necessary (in an anonymous form).
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

HR 116-712
VA Medicinal Cannabis Research Act of 2019

Bill from Previous Congress

HR 117-2916
VA Medicinal Cannabis Research Act of 2021

Bill from Previous Congress

HR 115-5520
VA Medicinal Cannabis Research Act of 2018
Feb 14, 2023
Introduced in House
Feb 14, 2023
Referred to the House Committee on Veterans' Affairs.
Mar 13, 2023
Referred to the Subcommittee on Health.
Apr 26, 2023

Latest Companion Bill Action

S 118-326
Motion by Senator Schumer to reconsider the vote by which cloture on the motion to proceed to S. 326 was not invoked (Record Vote No. 97) entered in Senate.
  • Bill from Previous Congress

    HR 116-712
    VA Medicinal Cannabis Research Act of 2019


  • Bill from Previous Congress

    HR 117-2916
    VA Medicinal Cannabis Research Act of 2021


  • Bill from Previous Congress

    HR 115-5520
    VA Medicinal Cannabis Research Act of 2018


  • February 14, 2023
    Introduced in House


  • February 14, 2023
    Referred to the House Committee on Veterans' Affairs.


  • March 13, 2023
    Referred to the Subcommittee on Health.


  • April 26, 2023

    Latest Companion Bill Action

    S 118-326
    Motion by Senator Schumer to reconsider the vote by which cloture on the motion to proceed to S. 326 was not invoked (Record Vote No. 97) entered in Senate.

Armed Forces and National Security

Related Bills

  • S 118-326: VA Medicinal Cannabis Research Act of 2023

VA Medicinal Cannabis Research Act of 2023

USA118th CongressHR-1003| House 
| Updated: 3/13/2023
VA Medicinal Cannabis Research Act of 2023 This bill requires the Department of Veterans Affairs (VA) to study the effects of cannabis on veterans who are enrolled in the VA health care system and have been diagnosed with post-traumatic stress disorder (PTSD) or chronic pain (i.e., eligible veterans). First, the bill requires the VA to conduct an observational, 18-month study on the effects of cannabis on the health outcomes of eligible veterans. The VA must report on the study and address whether it is able to meet criteria necessary to conduct clinical trials. Then, if the VA determines that it is able to proceed, it must carry out a series of clinical trials on the effects of cannabis appropriate for investigational use, as determined by the Food and Drug Administration, on the outcomes of eligible veterans. The VA must carry out a long-term observational study of the clinical trial participants. The VA may terminate the trials if it is unable to meet clinical guideline requirements or the trials would create excessive risk to participants. The VA must ensure that the study and trials are representative of the demographics of veterans in the United States, as determined by the most recent data from the American Community Survey of the Bureau of the Census. The study and trials must include mechanisms to ensure data preservation and registration as necessary (in an anonymous form).
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

HR 116-712
VA Medicinal Cannabis Research Act of 2019

Bill from Previous Congress

HR 117-2916
VA Medicinal Cannabis Research Act of 2021

Bill from Previous Congress

HR 115-5520
VA Medicinal Cannabis Research Act of 2018
Feb 14, 2023
Introduced in House
Feb 14, 2023
Referred to the House Committee on Veterans' Affairs.
Mar 13, 2023
Referred to the Subcommittee on Health.
Apr 26, 2023

Latest Companion Bill Action

S 118-326
Motion by Senator Schumer to reconsider the vote by which cloture on the motion to proceed to S. 326 was not invoked (Record Vote No. 97) entered in Senate.
  • Bill from Previous Congress

    HR 116-712
    VA Medicinal Cannabis Research Act of 2019


  • Bill from Previous Congress

    HR 117-2916
    VA Medicinal Cannabis Research Act of 2021


  • Bill from Previous Congress

    HR 115-5520
    VA Medicinal Cannabis Research Act of 2018


  • February 14, 2023
    Introduced in House


  • February 14, 2023
    Referred to the House Committee on Veterans' Affairs.


  • March 13, 2023
    Referred to the Subcommittee on Health.


  • April 26, 2023

    Latest Companion Bill Action

    S 118-326
    Motion by Senator Schumer to reconsider the vote by which cloture on the motion to proceed to S. 326 was not invoked (Record Vote No. 97) entered in Senate.
J. Luis Correa

J. Luis Correa

Democratic Representative

California

Cosponsors (11)
Christopher R. Deluzio (Democratic)Maxwell Frost (Democratic)Daniel T. Kildee (Democratic)Jasmine Crockett (Democratic)Nancy Mace (Republican)Val T. Hoyle (Democratic)Earl Blumenauer (Democratic)Seth Moulton (Democratic)Zoe Lofgren (Democratic)Jason Crow (Democratic)Jack Bergman (Republican)

Health Subcommittee, Veterans' Affairs Committee

Armed Forces and National Security

Related Bills

  • S 118-326: VA Medicinal Cannabis Research Act of 2023
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted